Cargando…
Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study
SUMMARY: We examined the effect of cumulative exposure to high doses of oral glucocorticoids on fracture risk. Compared to short-course users (daily dose ≥ 15 mg + cumulative < 1 g), heavy users (daily dose ≥ 15 mg + cumulative dose ≥ 1 g) had the highest risk of fracture. These patients should b...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857556/ https://www.ncbi.nlm.nih.gov/pubmed/29552730 http://dx.doi.org/10.1007/s11657-018-0424-x |
_version_ | 1783307485274177536 |
---|---|
author | Amiche, M. Amine Abtahi, Shahab Driessen, Johanna H. M. Vestergaard, Peter de Vries, Frank Cadarette, Suzanne M. Burden, Andrea M. |
author_facet | Amiche, M. Amine Abtahi, Shahab Driessen, Johanna H. M. Vestergaard, Peter de Vries, Frank Cadarette, Suzanne M. Burden, Andrea M. |
author_sort | Amiche, M. Amine |
collection | PubMed |
description | SUMMARY: We examined the effect of cumulative exposure to high doses of oral glucocorticoids on fracture risk. Compared to short-course users (daily dose ≥ 15 mg + cumulative < 1 g), heavy users (daily dose ≥ 15 mg + cumulative dose ≥ 1 g) had the highest risk of fracture. These patients should be monitored for fracture management strategies. PURPOSE: The effect of cumulative exposure to high daily doses of oral glucocorticoids on fracture risk remains debated. We therefore aimed to examine the hip fracture risk associated with short courses and heavy use of high-dosed oral glucocorticoids. METHODS: We conducted a population-based case-control study using the Danish National Health Service data, 1996–2011. Cases were those aged ≥ 18 years who sustained a hip (primary outcome) fracture (n = 81,342). Vertebral and forearm fractures were considered in secondary analyses. Controls (matched 1:1) were those without a fracture. Average daily dose (DD) and total cumulative dose (CD) were calculated among current oral glucocorticoid users. Among patients with a high daily dose (DD ≥ 15 mg), we identified short-course users as those with a CD < 1 g and heavy users as those with a CD ≥ 1 g. We estimated adjusted odds ratio (adj.OR) of fracture with current glucocorticoid use compared to never-use, using conditional logistic regression. RESULTS: A high DD (≥ 15 mg) and high CD (≥ 1 g) were independently associated with an increased hip fracture risk (adj.OR 2.5; 95% CI 2.2–2.9; adj.OR 1.6; 95% CI 1.5–1.8, respectively). However, the risk was substantially increased among heavy users (DD ≥ 15 mg and CD ≥ 1 g: adj.OR 2.9; 95% CI 2.5–3.4) as compared to short-course users (DD ≥ 15 mg and CD < 1 g: adj.OR 1.4; 95% CI 1.1–1.9). Associations were stronger for vertebral fractures, yet little association was identified for forearm fractures. CONCLUSION: Among patients receiving a high DD (≥ 15 mg), heavy users (≥ 1 g CD) showed the most substantial increase in hip fracture risk. Among those receiving high DD, a threshold of 1 g CD may identify heavy users that are candidates for focused fracture management services. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11657-018-0424-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5857556 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer London |
record_format | MEDLINE/PubMed |
spelling | pubmed-58575562018-03-21 Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study Amiche, M. Amine Abtahi, Shahab Driessen, Johanna H. M. Vestergaard, Peter de Vries, Frank Cadarette, Suzanne M. Burden, Andrea M. Arch Osteoporos Original Article SUMMARY: We examined the effect of cumulative exposure to high doses of oral glucocorticoids on fracture risk. Compared to short-course users (daily dose ≥ 15 mg + cumulative < 1 g), heavy users (daily dose ≥ 15 mg + cumulative dose ≥ 1 g) had the highest risk of fracture. These patients should be monitored for fracture management strategies. PURPOSE: The effect of cumulative exposure to high daily doses of oral glucocorticoids on fracture risk remains debated. We therefore aimed to examine the hip fracture risk associated with short courses and heavy use of high-dosed oral glucocorticoids. METHODS: We conducted a population-based case-control study using the Danish National Health Service data, 1996–2011. Cases were those aged ≥ 18 years who sustained a hip (primary outcome) fracture (n = 81,342). Vertebral and forearm fractures were considered in secondary analyses. Controls (matched 1:1) were those without a fracture. Average daily dose (DD) and total cumulative dose (CD) were calculated among current oral glucocorticoid users. Among patients with a high daily dose (DD ≥ 15 mg), we identified short-course users as those with a CD < 1 g and heavy users as those with a CD ≥ 1 g. We estimated adjusted odds ratio (adj.OR) of fracture with current glucocorticoid use compared to never-use, using conditional logistic regression. RESULTS: A high DD (≥ 15 mg) and high CD (≥ 1 g) were independently associated with an increased hip fracture risk (adj.OR 2.5; 95% CI 2.2–2.9; adj.OR 1.6; 95% CI 1.5–1.8, respectively). However, the risk was substantially increased among heavy users (DD ≥ 15 mg and CD ≥ 1 g: adj.OR 2.9; 95% CI 2.5–3.4) as compared to short-course users (DD ≥ 15 mg and CD < 1 g: adj.OR 1.4; 95% CI 1.1–1.9). Associations were stronger for vertebral fractures, yet little association was identified for forearm fractures. CONCLUSION: Among patients receiving a high DD (≥ 15 mg), heavy users (≥ 1 g CD) showed the most substantial increase in hip fracture risk. Among those receiving high DD, a threshold of 1 g CD may identify heavy users that are candidates for focused fracture management services. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11657-018-0424-x) contains supplementary material, which is available to authorized users. Springer London 2018-03-18 2018 /pmc/articles/PMC5857556/ /pubmed/29552730 http://dx.doi.org/10.1007/s11657-018-0424-x Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Amiche, M. Amine Abtahi, Shahab Driessen, Johanna H. M. Vestergaard, Peter de Vries, Frank Cadarette, Suzanne M. Burden, Andrea M. Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study |
title | Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study |
title_full | Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study |
title_fullStr | Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study |
title_full_unstemmed | Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study |
title_short | Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study |
title_sort | impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in denmark: a population-based case-control study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857556/ https://www.ncbi.nlm.nih.gov/pubmed/29552730 http://dx.doi.org/10.1007/s11657-018-0424-x |
work_keys_str_mv | AT amichemamine impactofcumulativeexposuretohighdoseoralglucocorticoidsonfractureriskindenmarkapopulationbasedcasecontrolstudy AT abtahishahab impactofcumulativeexposuretohighdoseoralglucocorticoidsonfractureriskindenmarkapopulationbasedcasecontrolstudy AT driessenjohannahm impactofcumulativeexposuretohighdoseoralglucocorticoidsonfractureriskindenmarkapopulationbasedcasecontrolstudy AT vestergaardpeter impactofcumulativeexposuretohighdoseoralglucocorticoidsonfractureriskindenmarkapopulationbasedcasecontrolstudy AT devriesfrank impactofcumulativeexposuretohighdoseoralglucocorticoidsonfractureriskindenmarkapopulationbasedcasecontrolstudy AT cadarettesuzannem impactofcumulativeexposuretohighdoseoralglucocorticoidsonfractureriskindenmarkapopulationbasedcasecontrolstudy AT burdenandream impactofcumulativeexposuretohighdoseoralglucocorticoidsonfractureriskindenmarkapopulationbasedcasecontrolstudy |